Race Modifies Survival Benefit of Guideline-based Treatment: Implications for Reducing Disparities in Muscle Invasive Bladder Cancer
Overview
Affiliations
Background: Black individuals with muscle-invasive bladder cancer (MIBC) experienced 21% lower odds of guideline-based treatment (GBT) and differences in treatment explain 35% of observed Black-White differences in survival. Yet little is known of how interactions between race/ethnicity and receipt of GBT drive within- and between-race survival differences.
Methods: Black, White, and Latino individuals diagnosed with nonmetastatic, locally advanced MIBC from 2004 to 2013 within the National Cancer Database were included. Guideline-based treatment was defined as the receipt including one or more of the following treatment modalities: radical cystectomy (RC), neoadjuvant chemotherapy with RC, RC with adjuvant chemotherapy, and/or chemoradiation based on American Urological Association guidelines. Cox proportional hazards model of mortality estimated effects of GBT status, race/ethnicity, and the GBT-by-race/ethnicity interaction, adjusting for covariates.
Results: Of the 54 910 MIBC individuals with 125 821 person-years of posttreatment observation (max = 11 years), 6.9% were Black, and 3.0% were Latino. Overall, 51.4%, 45.3%, and 48.5% of White, Black, and Latino individuals received GBT. Latino individuals had lower hazard of death compared to Black (HR 0.81, 95% CI 0.75-0.87) and White individuals (HR 0.92, 95% 0.86-0.98). With GBT, Latino and White individuals had similar outcomes (HR = 1.00, 95% 0.91-1.10) and both fared better than Black individuals (HR = 0.88, 95% 0.79-0.99 and HR = 0.88, 95% 0.83-0.94, respectively). Without GBT, Latino individuals fared better than White (HR = 0.85, 95% 0.77-0.93) and Black individuals (HR = 0.74, 95% 0.67-0.82) while White individuals fared better than Black individuals (HR = 0.87, 95% 0.83-0.92). Black individuals with GBT fared worse than Latinos without GBT (HR = 1.02, 95% 0.92-1.14), although not statistically significant.
Conclusion: Low GBT levels demonstrated an "under-allocation" of GBT to those who needed it most-Black individuals. Interventions to improve GBT allocation may mitigate race-based survival differences observed in MIBC.
Ladi-Seyedian S, Ghoreifi A, Konety B, Pohar K, Holzbeierlein J, Taylor J Cancers (Basel). 2024; 16(7).
PMID: 38610946 PMC: 11011163. DOI: 10.3390/cancers16071268.
Sereda Y, Alarid-Escudero F, Bickell N, Chang S, Colditz G, Hur C J Natl Cancer Inst Monogr. 2023; 2023(62):219-230.
PMID: 37947329 PMC: 11009510. DOI: 10.1093/jncimonographs/lgad021.
Washington 3rd S, Gregorich S, Meng M, Suskind A, Porten S Cancer Med. 2020; 9(22):8310-8317.
PMID: 32869516 PMC: 7666728. DOI: 10.1002/cam4.3429.